Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Laurens T van der Meer"'
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
Autor:
Britt M. T. Vervoort, Miriam Butler, Kari J.T. Grünewald, Dorette S. van Ingen Schenau, Trisha M. Tee, Luc Lucas, Alwin D. R. Huitema, Judith M. Boer, Beat C. Bornhauser, Jean-Pierre Bourquin, Peter M. Hoogerbrugge, Vincent H.J. van der Velden, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
IKZF1-deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1-loss on sensitivity to drugs used in contemporary treatment protocols has remained under
Externí odkaz:
https://doaj.org/article/70f5749bff5943bb9814e9df3159f0f2
Autor:
Willem P.J. Cox, Nils Evander, Dorette S. van Ingen Schenau, Gawin R. Stoll, Nadia Anderson, Lieke de Groot, Kari J.T. Grünewald, Rico Hagelaar, Miriam Butler, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
In pediatric acute lymphoblastic leukemia (ALL), mutations/deletions affecting the TP53 gene are rare at diagnosis. However, at relapse about 12% of patients show TP53 aberrations, which are predictive of a very poor outcome. Since p53-mediated apopt
Externí odkaz:
https://doaj.org/article/986ac4b3aae24d9999fc92fcd6366f17
Autor:
Miriam Butler, Britt M.T. Vervoort, Dorette S. van Ingen Schenau, Lieneke Jongeneel, Jordy C.G. van der Zwet, René Marke, Jules P.P. Meijerink, Blanca Scheijen, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Although long-term survival in pediatric acute lymphoblastic leukemia (ALL) currently exceeds 90%, some subgroups, defined by specific genomic aberrations, respond poorly to treatment. We previously reported that leukemias harboring deletions or muta
Externí odkaz:
https://doaj.org/article/bd62010cd4ac4cb38d96197bfa9e66ae
Autor:
Beat Bornhauser, Roland P. Kuiper, Steven M. Kornblau, Britt M.T. Vervoort, Jiangyan Yu, Rico Hagelaar, Fieke W Hoff, Frank N. van Leeuwen, Dorette van Ingen Schenau, Maria Pamela Dobay, Trisha M Tee, Laurens T. van der Meer, Silvia Jenni, Jules P.P. Meijerink, Jean-Pierre Bourquin, Miriam Butler
Publikováno v:
Blood, 138(23), 2383-2395. AMER SOC HEMATOLOGY
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Contains fulltext : 241347.pdf (Publisher’s version ) (Closed access) Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To
Autor:
Blanca Scheijen, Judith M. Boer, René Marke, Esther Tijchon, Dorette van Ingen Schenau, Esmé Waanders, Liesbeth van Emst, Laurens T. van der Meer, Rob Pieters, Gabriele Escherich, Martin A. Horstmann, Edwin Sonneveld, Nicola Venn, Rosemary Sutton, Luciano Dalla-Pozza, Roland P. Kuiper, Peter M. Hoogerbrugge, Monique L. den Boer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 102, Iss 3 (2017)
Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are associated with an increased relapse risk and poor outcome in B-cell precursor acute lymphoblastic leukemia. However, additional genetic events may either enhance or n
Externí odkaz:
https://doaj.org/article/4b9e33dbdf0346af888f8b42df273b6a
Autor:
Willem Cox, Miriam Butler, Dorette S van Ingen Schenau, Nadia Anderson, Lieke de Groot, Laurens T van der Meer, Frank N van Leeuwen
Publikováno v:
Blood. 140:3132-3133
Autor:
Trisha Tee, Titine Ruiter, Danique Wajon, Shuiyan Wu, Ahmed Dahaoui, Dorette S van Ingen Schenau, Laurens T van der Meer, Frank N van Leeuwen
Publikováno v:
Blood. 140:6343-6344
Autor:
Britt M T Vervoort, Miriam Butler, Dorette van Ingen Schenau, Vincent H.J. van der Velden, Beat Bornhauser, Jean-Pierre Bourquin, Laurens T van der Meer, Frank N van Leeuwen
Publikováno v:
Blood. 140:3465-3466
Publikováno v:
Trends in Endocrinology and Metabolism, 32, 6, pp. 367-381
Trends in Endocrinology and Metabolism, 32, 367-381
Trends in Endocrinology and Metabolism, 32, 367-381
Contains fulltext : 234011.pdf (Publisher’s version ) (Open Access) Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment response in therapy resistant cancers as well as mitigate treatment-related toxicities
Autor:
Miriam, Butler, Britt M T, Vervoort, Dorette S, van Ingen Schenau, Lieneke, Jongeneel, Jordy C G, van der Zwet, René, Marke, Jules P P, Meijerink, Blanca, Scheijen, Laurens T, van der Meer, Frank N, van Leeuwen
Publikováno v:
Frontiers in oncology. 12
Although long-term survival in pediatric acute lymphoblastic leukemia (ALL) currently exceeds 90%, some subgroups, defined by specific genomic aberrations, respond poorly to treatment. We previously reported that leukemias harboring deletions or muta